TG Therapeutics, Inc. (TGTX) Stock Rating Reaffirmed by HC Wainwright
TG Therapeutics, Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Tuesday. They currently have a $33.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $18.00. HC Wainwright’s price target points to a potential upside of 290.53% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $26.78.
TG Therapeutics (TGTX) traded down $0.20 during midday trading on Tuesday, reaching $8.45. The company’s stock had a trading volume of 895,200 shares, compared to its average volume of 1,563,184. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. equities research analysts forecast that TG Therapeutics will post -1.84 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/16/tg-therapeutics-inc-tgtx-stock-rating-reaffirmed-by-hc-wainwright.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Parametric Portfolio Associates LLC purchased a new position in shares of TG Therapeutics in the first quarter worth about $928,000. American International Group Inc. grew its stake in shares of TG Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 1,500 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of TG Therapeutics by 7.1% in the first quarter. Teachers Advisors LLC now owns 75,432 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 5,000 shares during the last quarter. Legal & General Group Plc grew its stake in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 384 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock worth $20,860,000 after purchasing an additional 246,404 shares during the last quarter. Hedge funds and other institutional investors own 49.58% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.